Regulatory Challenges of Individualized Therapies

Mainz, August 14, 2013 – As part of the Ci3 “Schaufenster” event series, the Paul-Ehrlich-Institute invites to an evening seminar on the challenges of drug approval in the age of individualized medicine. The event takes place on September 4, 5:30 to 7:30 pm at the Paul Ehrlich Institute in Langen.

The Ci3-Schaufenster series is a platform to promote the dialogue between research institutes, hospitals, biotech companies and the pharmaceutical industry that operate in the Rhine-Main area. Industry and academic partners open their doors to offer insights into their organizational structures, work and activities.

Ci3 (Cluster for Indivdualized ImmuneIntervention) is a regional consortium funded by the German Federal Ministry of Education and Research (BMBF) with more than 120 partners from industry, research, patient care and government agencies working towards individualized immune interventions for the treatment of life-threatening conditions such as cancer, autoimmune diseases and infections. Ci3 combines the outstanding scientific excellence and commercial expertise in the Rhine-Main Metropolitan Region to develop new immune intervention strategies with large economic potential and to position Ci3 among the prime immunology clusters in Europe.

On November 13, TRON will be the next cluster partner to invite the Ci3 community to a presentation on innovative concepts that usher new drugs and therapies into clinical trials.